Anthropic's Life Sciences team published drug discovery case studies and technical reports detailing collaborations with six organizations (BigHat Biosciences, Bristol Myers Squibb, Divergence Labs, Enveda, Generate Biomedicines, The Column Group), and disclosed the acquisition of the one-person company Mithril Medicine, marking the start of its own drug project for a rare form of childhood muscular dystrophy.
Confidence: High (80) · Event Time 2026-10-27
Rationale
- Covers multiple stages of the R&D pipeline, not just molecular design: Scientists at Generate used Claude Code to design CAR-T gene fragments that are approximately 70% shorter, with receptor counts in lab tests approximately 10 times higher than the original; Claude generated approximately 35,000 antibody designs for Divergence Labs almost autonomously over about a month, identifying candidates capable of binding and stripping IgE; BigHat prepared and tested approximately 1,010 variants in about 10 weeks, with the best version showing binding affinity improvements of more than 10 times.
- Non-experimental stages: Enveda had Claude review 1,061 pages of production documentation, finding all 11 issues identified by humans and flagging an additional 7 issues missed by human reviewers, reducing review time by 89%; a draft regulatory document was completed in 4 hours, a task that would typically take humans about three months. Bristol Myers Squibb used Claude to evaluate early clinical trial protocols and success probabilities.
- Mithril's founder used Claude to coordinate 11 external laboratories, advancing a muscular dystrophy candidate therapy from concept to mouse testing stage in less than 18 months; Anthropic stated that human clinical trials could begin as early as the end of 2028.
- Anthropic stated it will significantly expand this work and has already adjusted its model improvement priorities based on shortcomings revealed during these collaborations.
Usage
- Links to technical reports and preprints for each case are available in the original article. Anthropic also offers the Claude Science research workbench, Claude credits for life scientists, a life sciences validation program (allowing trusted institutions to use models with fewer safety restrictions), and an open call for guest researchers.
Risks
- Results are almost entirely preclinical, with drugs not yet tested in humans; data was published by Anthropic and its partners without independent review.
- Cases were selected by Anthropic and contain promotional elements; the acquisition price for Mithril was not disclosed.